The HERCULES trial shows pembrolizumab plus chemotherapy produces a 39.4% response rate in advanced penile cancer, offering ...

mRNA-4359 combined with pembrolizumab achieved a 24% ORR and 67% efficacy in PD-L1 positive melanoma patients. The study ...

When the organization now called the European Society for Medical Oncology (ESMO) opens its 50th anniversary Congress ...

In a small phase II trial, radiation-free treatment with pembrolizumab (Keytruda) and platinum-based chemotherapy alone ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-B96 trial, ...

"ESMO 2025: Anticipated Phase II data debut for Eikon’s NSCLC candidate" was originally created and published by Clinical ...

While immune checkpoint inhibitors (anti-PD-1 +/- anti-CTLA-4) are approved as first line treatment for microsatellite ...

Merck leads U.S. pharma in 2025, but faces Keytruda patent loss by 2028. Click for my look at MRK stock ahead of its upcoming ...

Poster 2: Second-Generation Immune Checkpoint Inhibitors (Class II TRBC Compound) Title : A novel tetra-specific pembrolizumab-based immunotherapeutic Abstract Number : 1014 Session Date and Time : ...

FDA fast track designation for NG-350A aims to expedite its development for mismatch repair-proficient locally advanced ...